Sponsor:
Miltenyi Biomedicine GmbH
Code:
NCT04792489
Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed Diffuse Large B Cell Lymphoma
High Grade B-cell Lymphoma (HGBCL)
Primary Mediastinal B-cell Lymphoma (PMBCL)
Transformed Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
zamtocabtagene autoleucel (MB-CART2019.1)
Cyclophosphamide
Fludarabine
Bendamustine
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by Miltenyi Biomedicine GmbH on 2025-04-24.